MY113489A - Reversible protease inhibitors - Google Patents

Reversible protease inhibitors

Info

Publication number
MY113489A
MY113489A MYPI96001076A MYPI19961076A MY113489A MY 113489 A MY113489 A MY 113489A MY PI96001076 A MYPI96001076 A MY PI96001076A MY PI19961076 A MYPI19961076 A MY PI19961076A MY 113489 A MY113489 A MY 113489A
Authority
MY
Malaysia
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
specific
Prior art date
Application number
MYPI96001076A
Other languages
English (en)
Inventor
Lee Klaus Jeffrey
T Palmer James
Rasnick David
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of MY113489A publication Critical patent/MY113489A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI96001076A 1995-03-24 1996-03-22 Reversible protease inhibitors MY113489A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
MY113489A true MY113489A (en) 2002-03-30

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI96001076A MY113489A (en) 1995-03-24 1996-03-22 Reversible protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (no)
JP (1) JPH11503417A (no)
KR (1) KR19980703261A (no)
CN (1) CN1071751C (no)
AU (1) AU713492B2 (no)
CA (1) CA2216151A1 (no)
CZ (1) CZ298197A3 (no)
IL (1) IL117638A0 (no)
MY (1) MY113489A (no)
NO (1) NO311573B1 (no)
NZ (1) NZ305626A (no)
PL (1) PL322409A1 (no)
TW (1) TW470750B (no)
WO (1) WO1996030353A1 (no)
ZA (1) ZA962336B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251714A1 (en) 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
EE9900036A (et) * 1996-07-30 1999-08-16 Arris Pharmaceutical Corporation Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
DE19817461A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
WO2000007991A1 (en) * 1998-08-04 2000-02-17 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ATE254105T1 (de) * 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
ES2199856T3 (es) * 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
EP1309591B1 (en) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US6369032B1 (en) 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
US20020107266A1 (en) * 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
JP2005504078A (ja) * 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規化合物および組成物
MXPA04004450A (es) 2001-11-14 2004-08-11 Aventis Pharma Inc Nuevos compuestos y composiciones como inhibidores de catepsina s.
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
US8791235B2 (en) * 2008-05-21 2014-07-29 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
DK2697246T3 (en) 2011-04-15 2018-05-28 Genesis Tech Limited SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
KR101309578B1 (ko) * 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
TW201940493A (zh) * 2018-01-19 2019-10-16 日商大阪曹達股份有限公司 有機矽化合物，及使用其之橡膠組成物
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
EP0817778A1 (en) 1998-01-14
CZ298197A3 (cs) 1998-03-18
NZ305626A (en) 2000-01-28
PL322409A1 (en) 1998-01-19
CN1071751C (zh) 2001-09-26
NO974403L (no) 1997-11-17
NO311573B1 (no) 2001-12-10
TW470750B (en) 2002-01-01
CN1184472A (zh) 1998-06-10
WO1996030353A1 (en) 1996-10-03
JPH11503417A (ja) 1999-03-26
IL117638A0 (en) 1996-07-23
AU5367496A (en) 1996-10-16
KR19980703261A (ko) 1998-10-15
AU713492B2 (en) 1999-12-02
NO974403D0 (no) 1997-09-23
ZA962336B (en) 1996-07-31
CA2216151A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
MY113489A (en) Reversible protease inhibitors
IL112759A0 (en) Novel cysteine protease inhibitors
ZA964751B (en) Reversible cysteine protease inhibitors
AU5122196A (en) Cysteine protease inhibitor
PL331533A1 (en) Cysteine protease inhibitors
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
NO20006716D0 (no) Proteaseinhibitorer
AU7127298A (en) Serine protease inhibitors
AU1266495A (en) Cysteine protease inhibitors containing heterocyclic leaving groups
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
BG104885A (en) Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
EP0975353A4 (en) PEPTIDYL-2-AMINO-1HYDROXYALKANESULPHONIC ACIDS AS CYSTEIN PROTEASE INHIBITORS
ZA971733B (en) Serine protease inhibitors.
EP0923535A4 (en) CYSTEINE PROTEASE INHIBITORS
AU6458396A (en) Phosphorous-containing cysteine and serine protease inhibitors
ZA971667B (en) Serine protease inhibitors.
EP1032393A4 (en) QUINOLIN-CONTAINING ALPHA-KETOAMIDE-BASED INHIBITORS OF CYSTEIN AND SERINE PROTEASE
IL139187A0 (en) Cysteine protease inhibitors
IL123771A0 (en) Metal complexes as cysteine protease inhibitors
GB9603217D0 (en) Serine protease inhibitors
NO975534D0 (no) Imidazo-£1,5|-pyridin-avledete serinproteaseinhibitorer
ATE311440T1 (de) Bacillus-proteasen
ZA969078B (en) Inhibitors of cysteine protease.
DE69635608D1 (de) Bacillus proteasen
AU2234497A (en) Novel protease inhibitors derived from guamerin